References
- JanesRHJrNiederhuberJEChmielJSNational patterns of care for pancreatic cancer. Results of a survey by the Commission on CancerAnn Surg199622332612728604906
- CalleEERodriguezCWalker-ThurmondKThunMJOverweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adultsN Engl J Med2003348171625163812711737
- ShaibYDavilaJNaumannCEl-SeragHThe impact of curative intent surgery on the survival of pancreatic cancer patients: a U.S. Population-based studyAm J Gastroenterol200710271377138217403071
- BurrisHAIIIMooreMJAndersenJImprovements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialJ Clin Oncol1997156240324139196156
- KastrinosFMukherjeeBTayobNRisk of pancreatic cancer in families with Lynch syndromeJAMA2009302161790179519861671
- FerroneCRLevineDATangLHBRCA germline mutations in Jewish patients with pancreatic adenocarcinomaJ Clin Oncol200927343343819064968
- BaoYMichaudDSPhysical activity and pancreatic cancer risk: a systematic reviewCancer Epidemiol Biomarkers Prev200817102671268218843009
- MichaudDSGiovannucciEWillettWCColditzGAStampferMJFuchsCSPhysical activity, obesity, height, and the risk of pancreatic cancerJAMA2001286892192911509056
- LiDMorrisJSLiuJBody mass index and risk, age of onset, and survival in patients with pancreatic cancerJAMA2009301242553256219549972
- GumbsAAObesity, pancreatitis, and pancreatic cancerObes Surg20081891183118718563497
- SmeenkHGTranTCErdmannJvan EijckCHJeekelJSurvival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?Langenbecks Arch Surg200539029410315578211
- MuDQPengSYWangGFRisk factors influencing recurrence following resection of pancreatic head cancerWorld J Gastroenterol200410690690915040043
- ShibataKMatsumotoTYadaKSasakiAOhtaMKitanoSFactors predicting recurrence after resection of pancreatic ductal carcinomaPancreas2005311697315968250
- AbramsRALowyAMO’ReillyEMWolffRAPicozziVJPistersPWCombined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statementAnn Surg Oncol20091671751175619390900
- KalserMHEllenbergSSPancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resectionArch Surg198512088999034015380
- KlinkenbijlJHJeekelJSahmoudTAdjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative groupAnn Surg1999230677678210615932
- GarofaloMCRegineWFTanMTOn statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancerAnn Surg2006244233233316858208
- NeoptolemosJPStockenDDFriessHfor the European Study Group for Pancreatic CancerA randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancerN Engl J Med2004350121200121015028824
- ChotiMAdjuvant therapy for pancreatic cancer – the debate continuesN Engl J Med2004350121249125115028829
- CraneCHBen-JosefESmallWJrChemotherapy for pancreatic cancerN Engl J Med2004350262713271515218575
- KosugeTKiuchiTMukaiKKakizoeTfor the Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP)A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancerJpn J Clin Oncol200636315916516490736
- OettleHPostSNeuhausPAdjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trialJAMA2007297326727717227978
- UenoHKosugeTMatsuyamaYA randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic CancerBr J Cancer2009101690891519690548
- NeoptolemosJBüchlerMStockenDDESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. ASCO Annual MeetingJ Clin Oncol200927Suppl 18 Abstract LBA4505.
- VaradhacharyGRTammEPAbbruzzeseJLBorderline resectable pancreatic cancer: definitions, management, and role of preoperative therapyAnn Surg Oncol20061381035104616865597
- UjikiMBTalamontiMSGuidelines for the surgical management of pancreatic adenocarcinomaSemin Oncol200734431132017674959
- WhiteRRHurwitzHIMorseMANeoadjuvant chemoradiation for localized adenocarcinoma of the pancreasAnn Surg Oncol200181075876511776488
- AmmoriJBCollettiLMZalupskiMMSurgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreasJ Gastrointest Surg20037676677213129554
- JessupJMSteeleGJrMayerRJNeoadjuvant therapy for unresectable pancreatic adenocarcinomaArch Surg199312855595648098206
- PilepichMVMillerHHPreoperative irradiation in carcinoma of the pancreasCancer Biol Ther198046919451949
- BrunnerTBGrabenbauerGGBaumUHohenbergerWSauerRAdjuvant and neoadjuvant radiochemotherapy in ductal pancreatic carcinomaStrahlenther Onkol2000176626527310897253
- WeeseJLNussbaumMLPaulARIncreased resectability of locally advanced pancreatic and periampullary carcinoma with neoadjuvant chemoradiotherapyInt J Pancreatol199071–31771852081923
- MassuccoPCapussottiLMagninoAPancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survivalAnn Surg Oncol20061391201120816955382
- BrownKMSiripurapuVDavidsonMChemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinomaAm J Surg2008195331832118308038
- WilkowskiRThomaMBrunsCWagnerAHeinemannVChemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancerJOP20067434936016832132
- TalamontiMSSmallWJrMulcahyMFA multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinomaAnn Surg Oncol200613215015816418882
- IokaTTanakaSNakaizumiANishiyamaKA phase I trial of chemoradiation therapy with concurrent full dose gemcitabine for unresectable locally advanced pancreatic adenocarcinomaJ Clin Oncol2005231654209
- SmallWJrBJFreedmanGMFull-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trialJ Clin Oncol200826694294718281668
- RegineWFWinterKAAbramsRAFluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trialJAMA200829991019102618319412
- LoehrerPJPowellMECardenesHRA randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201J Clin Oncol200826Suppl 20 Abstract 4506.
- MartiJLHochesterHSHiotisSPDonahueBRyanTNewmanEPhase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancerAnn Surg Oncol200815123521353118830756
- ChauffertBMornexFBonnetainFPhase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO studyAnn Oncol20081991592159918467316
- WhiteRRXieHBGottfriedMRSignificance of histological response to preoperative chemoradiotherapy for pancreatic cancerAnn Surg Oncol200512321422115827813
- PedduPQuagliaAKanePAKaraniJBRole of imaging in the management of pancreatic massCrit Rev Oncol Hematol2009701122318951813
- TammECharnsangavejCSzklarukJAdvanced 3-D imaging for the evaluation of pancreatic cancer with multidetector CTInt J Gastrointest Cancer2001301–2657112489581
- MaiseyNRWebbAFluxGDFDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot studyBr J Cancer200083328729310917540
- MercadanteSNicosiaFCeliac plexus block: a reappraisalReg Anesth Pain Med199823137489552777
- SakorafasGHTsiotouAGSarrMGIntraoperative celiac plexus block in the surgical palliation for unresectable pancreatic cancerEur J Surg Oncol199925442743110419716
- EisenbergECarrDBChalmersTCNeurolytic celiac plexus block for treatment of cancer pain: A meta-analysisAnesth Analg1995822902957818115
- LillemoeKDCameronJLKaufmanHSChemical splanchnicectomy in patients with unresectable pancreatic cancer: a prospective randomized trialAnn Surg199321754474557683868
- MatsumotoJTraversoLWExocrine function following the whipple operation as assessed by stool elastaseJ Gastrointest Surg20061091225122917114009
- PerezMMNewcomerADMoertelCGGoVLDimagnoEPAssessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancerCancer19835223463526305473
- BrunoMJHaverkortEBTijssenGPPlacebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head regionGut19984292969505892
- BachmannJKettererKMarschCPancreatic cancerrelated cachexia: influence on metabolism and correlation to weight loss and pulmonary functionBMC Cancer200928925519635171
- RobinsonDWJrEisenbergDFCellaDZhaoNde BoerCDeWitteMThe prognostic significance of patient-reported outcomes in pancreatic cancer cachexiaJ Support Oncol20086628329018724539
- HeiskanenTMatzkeSHaakanaSGergovMVuoriEKalsoETransdermal fentanyl in cachectic cancer patientsPain20091441–221822219442446
- MannCDThomassetSCJohnsonNACombined biliary and gastric bypass procedures as effective palliation for unresectable malignant diseaseANZ J Surg200979647147519566872
- CanBSarayACaglikulekçiMSaranYEffects of obstructive jaundice on the peripheral nerve: an ultrastructural study in ratsEur Surg Res200436422623315263828
- CostamagnaGPandolfiMEndoscopic stenting for biliary and pancreatic malignanciesJ Clin Gastroenterol200438596714679329
- BallingerABMcHughMCatnachSMSymptom relief and quality of life after stenting for malignant bile duct obstructionGut1994354674707513672
- TibbleJACairnsSRRole of endoscopic endoprostheses in proximal malignant biliary obstructionJ Hepatobiliary Pancreat Surg20018211812311455466
- SukKTKimHSKimJWRisk factors for cholecystitis after metal stent placement in malignant biliary obstructionGastrointest Endosc200664452252916996343
- MossACMorrisEMac MathunaPPalliative biliary stents for obstructing pancreatic carcinomaCochrane Database Syst Rev20062CD004200
- PovoskiSPKarpehMSJrConlonKCBlumgartLHBrennanMFAssociation of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomyAnn Surg1999230213114210450725
- SohnTAYeoCJCameronJLPittHALillemoeKDDo preoperative biliary stents increase postpancreaticoduodenectomy complications?J Gastrointest Surg200043258267 discussion 267–258.10769088
- HochwaldSNBurkeECJarnaginWRFongYBlumgartLHAssociation of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinomaArch Surg1999134326126610088565
- MumtazKHamidSJafriWEndoscopic retrograde cholangiopan-creaticography with or without stenting in patients with pancreaticbiliary malignancy, prior to surgeryCochrane Database Syst Rev20073CD00600117636818
- MallinsonCNRakeMOCockingJBChemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trialBr Med J19802816255158915917004559
- KelsenDHudisCNiedzwieckiDA phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinomaCancer19916859659691833042
- CullinanSMoertelCEWieandHSA phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatinCancer19906510220722122189551
- FungMCIshiguroHTakayamaSMorizaneTAdachiSSakataTSurvival benefit of chemotherapy treatment in advanced pancreatic cancer: a meta-analysisProc Am Soc Clin Oncol2003221155
- GrunewaldRKantarjianHKeatingMJAbbruzzeseJTarassoffPPlunkettWPharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (Gemcitabine) administration in leukemiaCancer Res19905021682368262208147
- TemperoMPlunkettWRuiz Van HaperenVRandomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinomaJ Clin Oncol200321183402340812885837
- PoplinEFengYBerlinJPhase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology GroupJ Clin Oncol200927233778378519581537
- LouvetCAndrèTLledoGGemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II studyJ Clin Oncol2002201512151811896099
- LouvetCLabiancaRHammelPGemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trialJ Clin Oncol200523153509351615908661
- ColucciGLabiancaRDi CostanzoFA randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas – GOIM/GISCAD/GOIRC) study. 2009 ASCO Annual MeetingJ Clin Oncol200927Suppl 15 Abstract 4504.
- NietoJGrossbandMLKozuchPMetastatic pancreatic cancer 2008: is the glass less empty?Oncologist200813556257618515741
- MooreMJGoldsteinDHammJErlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol2007251960196617452677
- HeinemannVBoeckSHinkeALabiancaRLouvetCMeta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancerBMC Cancer200888218373843
- HeinemannVLabiancaRHinkeALouvetCIncreased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter studyAnn Oncol200718101652165917660491
- WangXNiQJinMGemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancerZhonghua Zhong Liu Za Zhi200224440440712408777
- ColucciGGiulianiFGebbiaVGemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia MeridionaleCancer200294490291011920457
- Xie deRLiangHLWangYGuoSSMeta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine aloneChin J Dig Dis200671495416412038
- CartwrightTHCohnAVarkeyJAPhase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancerJ Clin Oncol20022016016411773165
- HerrmannRBodokgGRuhstallerTGemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology GroupJ Clin Oncol200725162212221717538165
- XiongHQRosenbergALoBuglioACetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trialJ Clin Oncol200422132610261615226328
- OettleHPetzerUStielerJOxaliplatin/Folinic acid/5-fluoroouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO-003)Proc Am Soc Clin Oncol2005 Abstract 4031.
- StrimpakosASaifMWSyrigosKNPancreatic cancer: from molecular pathogenesis to targeted therapyCancer Metastasis Rev200827349552218427734
- IannittiDDipetrilloTAkemanPErlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: A phase I studyAm J Clin Oncol20052857057516317266
- EpelbaumRSchnaiderJGluzmanAErlotinib as a single-agent therapy in patients with advanced pancreatic cancerPresented at: the ASCO Gastrointestinal Cancer symposium2007Orlando, Florida
- KulkeMHBlaszkowskyLSRyanDPCapecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancerJ Clin Oncol200725304787479217947726
- PhilipPAMooneyMJaffeDConsensus report of the National Cancer Institute clinical trials planning meeting on pancreas cancer treatmentJ Clin Oncol200927335660566919858397
- BurtnessBAPowellMBerlinJPhase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor receptor (EGF-r) : Eastern Cooperative Oncology [Meeting Abstracts]J Clin Oncol200725Suppl 18451917925545
- KindlerHLFribergGSinghDAPhase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancerJ Clin Oncol200523318033804016258101
- KindlerHLNiedzwieckiDHollisDA double-blind, placebo controlled randomized phase III gemcitabine + bevacisumab versus gemcitabien versus placeboJ Clin Oncol200725185450817906219
- WallaceJALockerGNattamSSorafenib plus gemcitabine for advanced pancreatic cancer: a phase II trial of the University of Chicago phase II consortiumJ Clin Oncol200725S 224
- O’ReillyEMNiedzwieckiDHollisDRA phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603ASCO Annual Meeting2008
- BruneKHongSMLiAGenetic and epigenetic alterations of familial pancreatic cancersCancer Epidemiol Biomarkers Prev200817123536354219064568
- PietrasKRubinKSjoblomTInhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapyCancer Res200262195476548412359756
- MantoniTSSchendelRRRödelFStromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinomaCancer Biol Ther2008711 [Epub ahead of print].
- HwangRFMooreTArumugamTCancer-associated stromal fibroblasts promote pancreatic tumor progressionCancer Res200868391892618245495
- Von HoffDDRamanathanRBoradMSPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study. ASCO Annual MeetingJ Clin Oncol200927Suppl 15 Abstract 4525.
- MaitraANab-paclitaxel targets tumor stroma and results, combined with gemcitabine, in high efficacy against pancreatic cancer modelsAACR20091117C246
- MaréchalRMackayJRLaiRHuman equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinomaClin Cancer Res20091582913291919318496
- BergmanAMAdemaABalzariniJAntiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor modelsInvest New Drugs2010112 [Epub ahead of print].
- PecherGHaringAKaiserLThielEMucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trialCancer Immunol Immunother20025111–1266967312439613
- HechtJRBedfordRAbbruzzeseJLA phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinomaClin Cancer Res20039255556112576418
- WobserMKeikavoussiPKunzmannVWeiningerMAndersenMHBeckerJCComplete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivinCancer Immunol Immunother200655101294129816315030
- MiyazawaMOhsawaRTsunodaTPhase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancerCancer Sci2010101243343919930156
- YangASMonkenCELattimeECIntratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigenCancer Res200363206956696114583497
- JemalASiegelRWardECancer statistics, CACancer J Clin20085827196
- BudihartoTHaustermansKVan CutsemEA phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinomaRadiat Oncol200833018808686
- CraneCHAJEvansDBIs the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?Int J Radiat Oncol Biol Phys20025251293130211955742
- McGinnCJZalupskiMMRadiation therapy with once-weekly gemcitabine in pancreatic cancer: current status of clinical trialsInt J Radiat Oncol Biol Phys200356Suppl 4S10S15
- TaberneroJMacarullaTChanging the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical developmentJ Clin Oncol200927335487549119858387
- Rocha LimaCMGreenMRRotcheRIrinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rateJ Clin Oncol200422183776378315365074
- HashimotoKUenoHIkedaMDo recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?Oncology2009773–421722319729980
- BakkevoldKEArnesjoBDahlOKambestadBAdjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater--results of a controlled, prospective, randomised multicentre studyEur J Cancer199329A56987038471327
- YeungRSWeeseJLHoffmanJPNeoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A phase II studyCancer1993727212421338374871
- KamthanAGMorrisJCDaltonJCombined modality therapy for stage II and stage III pancreatic carcinomaJ Clin Oncol1997158292029279256136
- WhiteRLeeCAnscherMPreoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreasAnn Surg Oncol199961384510030414
- BajettaEDi BartolomeoMStaniSCChemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility studyInt J Radiat Oncol Biol Phys199945228528910487547
- WaneboHJGlicksmanASVezeridisMPPreoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancerArch Surg20001351818710636353
- KimHJCzischkeKBrennanMFConlonKCDoes neoadjuvant chemoradiation downstage locally advanced pancreatic cancer?J Gastrointest Surg20026576376912399067
- RauHGWichmannMWWilkowskiRSurgical therapy of locally advanced and primary inoperable pancreatic carcinoma after neoadjuvant preoperative radiochemotherapyChirurg200273213213711974476
- AristuJCanonRPardoFSurgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancerAm J Clin Oncol2003261303612576921
- WilkowskiRThomaMSchauerRWagnerAHeinemannVEffect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancerWorld J Surg10200428101011101815573257
- Sa CunhaARaultALaurentCAdhouteXVendrelyVBéllannéeGBrunetRColletDMassonBSurgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreasJ Am Coll Surg2005201335936516125068
- DelperoJRTurriniOLocally advanced pancreatic adenocarcinoma. Chemoradiotherapy, reevaluation and secondary resectionCancer Radiother2006106–746247016987678
- AdhouteXSmithDVendrelyVSubsequent resection of locally advanced pancreatic carcinoma after chemoradiotherapyGastroenterol Clin Biol200630222423016565654
- TinklDGrabenbauerGGGolcherHDownstaging of pancreatic carcinoma after neoadjuvant chemoradiationStrahlenther Onkol2009185557–6655756619756421
- BerlinJDCatalanoPThomasJPKuglerJWHallerDGBensonABIIIPhase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297J Clin Oncol200220153270327512149301
- ReissHHelmANiedergethmannMSchmidt-WolfIMoikMHammerCA randomized, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs gemcitabine in patients with advanced pancreatic cancer. ASCO Annual MeetingJ Clin Oncol200523Suppl 16 Abstract LBA4009.
- CunninghamDChauIStockenDDPhase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancerJ Clin Oncol200927335513551819858379
- HeinemannVQuietzschDGieselerFRandomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancerJ Clin Oncol2006242439463952
- StathopoulosGPSyrigosKAravantinosGA multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancerBr J Cancer200695558759216909140
- Abou-AlfaGKLetourneauRHarkerGRandomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancerJ Clin Oncol200624274441444716983112
- ReniMCordioSMilandriCGemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trialLancet Oncol20056636937615925814
- OettleHRichardsDRamanathanRKA phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancerAnn Oncol200516101639164516087696
- BramhallSRRosemurgyABrownPDBowryCBuckelsJAMarimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trialJ Clin Oncol200119153447345511481349
- BramhallSRSchultzJNemunaitisJBrownPDBailletMBuckelsJAA double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancerBr J Cancer200287216116712107836
- MooreMJHammJDanceyJComparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol200321173296330212947065
- Van CutsemEvandeVeldeKarasekPPhase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancerJ Clin Oncol20042281430143815084616